Regarding snakebite: There's a brief response to the linked Nature article which argues that using recombinant antibodies could bring the cost of a broad-spectrum antivenom down to $30-150 per treatment vs the $60-600 typical for current serum-derived technology: https://www.nature.com/articles/538041e
That response was from 18 months ago, and some pretty big advances have been made in cell-free protein synthesis since then, so I suspect that a conservative estimate of the cost of recombinant antivenoms would be significantly lower (cell culture expenses are a massive chunk of biologic production costs).
Regarding snakebite: There's a brief response to the linked Nature article which argues that using recombinant antibodies could bring the cost of a broad-spectrum antivenom down to $30-150 per treatment vs the $60-600 typical for current serum-derived technology: https://www.nature.com/articles/538041e That response was from 18 months ago, and some pretty big advances have been made in cell-free protein synthesis since then, so I suspect that a conservative estimate of the cost of recombinant antivenoms would be significantly lower (cell culture expenses are a massive chunk of biologic production costs).